GlaxoSmithKline (GSK ... in product management for the Near East-East Africa in Boehringer Ingelheim. In 2002 he joined Schering Plough and had various positions including running the company ...

The era of mega-mergers Since the turn of the millennium, Pfizer has embarked on a series of mega-mergers, gobbling up Warner-Lambert in 2000, Pharmacia and Upjohn in 2002, Wyeth in 2009 ...

Am J Health Syst Pharm. 2006;63(19):1852-1857. Ketoconazole Likely absorbed in stomach because acidic medium required for absorption b Absorption likely to be negligible; consider alternative ...

30, 2023, to June 30, 2024, the managers sold out of three positions (GSK PLC, BCE ... first as a financials analyst, and from 2002 through 2017 as director of global research.

OpenSecrets is 100% funded through the generosity of donors.

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.

GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare Conference, the European healthcare giant noted there ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK is nearing a $1bn deal to buy a US biotech developing a treatment for rare gastrointestinal tumours ...